LIFECORE BIOMEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.595 USD | -0.68% |
|
-1.42% | +6.54% |
| Apr. 19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
| Apr. 01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
Valuation
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 291.8 | 320.7 | 351.1 | 291 | 240.7 | 201.5 | - | - |
| Enterprise Value (EV) 1 | 291.8 | 320.7 | 351.1 | 291 | 240.7 | 201.5 | 201.5 | 201.5 |
| P/E ratio | 1,000 x | -8.39 x | -10.7 x | -2.99 x | -2.33 x | 30 x | 11.4 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.52 x | 0.54 x | 0.65 x | 1.57 x | 2.33 x | 1.6 x | 1.39 x | 1.23 x |
| EV / Revenue | 0.52 x | 0.54 x | 0.65 x | 1.57 x | 2.33 x | 1.6 x | 1.39 x | 1.23 x |
| EV / EBITDA | 11.2 x | 14.6 x | 11.2 x | 12.6 x | 41.4 x | 12.5 x | 7.22 x | 6.48 x |
| EV / FCF | - | -7.33 x | -40.1 x | - | -4.36 x | 95.1 x | 13.8 x | - |
| FCF Yield | - | -13.6% | -2.49% | - | -22.9% | 1.05% | 7.26% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 29,183 | 29,182 | 29,333 | 29,483 | 30,319 | 30,547 | - | - |
| Reference price 2 | 10.00 | 10.99 | 11.97 | 9.870 | 7.940 | 6.595 | 6.595 | 6.595 |
| Announcement Date | 7/30/19 | 8/11/20 | 7/28/21 | 8/10/22 | 8/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 557.6 | 590.4 | 544.2 | 185.8 | 103.3 | 126.2 | 145.4 | 164.3 |
| EBITDA 1 | 26.05 | 22.02 | 31.42 | 23.02 | 5.809 | 16.13 | 27.91 | 31.07 |
| EBIT 1 | 5.475 | -38.54 | -13.5 | -38.04 | -26.08 | 9.096 | 21.9 | - |
| Operating Margin | 0.98% | -6.53% | -2.48% | -20.47% | -25.26% | 7.21% | 15.07% | - |
| Earnings before Tax (EBT) 1 | 3.64 | -51.31 | -40.47 | - | -68.7 | 7.631 | 20.98 | - |
| Net income 1 | 0.411 | -38.19 | -32.66 | -97.24 | -102.2 | 6.868 | 18.88 | - |
| Net margin | 0.07% | -6.47% | -6% | -52.34% | -98.96% | 5.44% | 12.99% | - |
| EPS 2 | 0.0100 | -1.310 | -1.120 | -3.300 | -3.410 | 0.2200 | 0.5800 | - |
| Free Cash Flow 1 | - | -43.73 | -8.752 | - | -55.22 | 2.118 | 14.63 | - |
| FCF margin | - | -7.41% | -1.61% | - | -53.47% | 1.68% | 10.07% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | 13.13% | 52.41% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 30.84% | 77.49% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 7/30/19 | 8/11/20 | 7/28/21 | 8/10/22 | 8/31/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: May | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 137.8 | 139.8 | 128.8 | 43.45 | 53.07 | 47.63 | 43.36 | 38.8 | 27.6 | 31.55 | 24.42 | 29.76 | 35.66 | 36.36 | 28.62 |
| EBITDA 1 | 7.61 | 12.11 | 4.422 | 8.304 | 6.361 | 6.02 | -1.057 | -0.357 | 1.451 | 3.727 | -1.989 | 2.842 | 6.892 | 5.913 | 0.354 |
| EBIT 1 | -0.793 | 1.231 | -3.808 | 4.141 | -3.751 | -35.68 | -8.157 | -7.906 | -9.699 | -5.026 | -4.13 | 2.635 | 4.799 | 5.792 | - |
| Operating Margin | -0.58% | 0.88% | -2.96% | 9.53% | -7.07% | -74.93% | -18.81% | -20.38% | -35.14% | -15.93% | -16.91% | 8.85% | 13.46% | 15.93% | - |
| Earnings before Tax (EBT) 1 | -5.715 | -3.443 | -11.59 | -41.26 | -7.382 | -36.4 | -12 | -12.44 | -15.39 | -33.57 | -4.5 | 2.24 | 4.434 | 5.457 | - |
| Net income 1 | -5.498 | -2.868 | -9.477 | -38.44 | -12.85 | -36.47 | -12.06 | -12.45 | -15.46 | -36.13 | -4.05 | 2.016 | 3.99 | 4.911 | - |
| Net margin | -3.99% | -2.05% | -7.36% | -88.47% | -24.21% | -76.58% | -27.83% | -32.08% | -56.02% | -114.53% | -16.59% | 6.77% | 11.19% | 13.51% | - |
| EPS 2 | -0.1900 | -0.1000 | -0.3200 | -1.300 | -0.4300 | -1.240 | -0.4100 | -0.4200 | -0.5100 | -1.190 | -0.1300 | 0.0700 | 0.1300 | 0.1600 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/7/21 | 7/28/21 | 9/29/21 | 1/5/22 | 4/5/22 | 8/10/22 | 10/6/22 | 3/16/23 | 6/1/23 | 8/31/23 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -43.7 | -8.75 | - | -55.2 | 2.12 | 14.6 | - |
| ROE (net income / shareholders' equity) | - | -3.03% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 44.7 | 26.7 | 23.8 | 28.1 | 20.8 | 18 | 20 | - |
| Capex / Sales | 8.02% | 4.52% | 4.37% | 15.14% | 20.11% | 14.26% | 13.76% | - |
| Announcement Date | 7/30/19 | 8/11/20 | 7/28/21 | 8/10/22 | 8/31/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.595
USD
Average target price
6
USD
Spread / Average Target
-9.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.54% | 201M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- LFCR Stock
- Financials Lifecore Biomedical, Inc.
